Corrigendum to "Beneficial effect of a chronic treatment with rimonabant on pancreatic function and β-cell morphology in Zucker Fatty rats" [Eur. J. Pharmacol. 66 (2009) 314-320] (DOI:10.1016/j.ejphar.2009.05.024);Beneficial effect of a chronic treatment with rimonabant on pancreatic function and β-cell morphology in Zucker Fatty rats

European Journal of Pharmacology

Volumn 616, Issue 1-3, 2009, Pages 314-320

  Duvivier, Valérie F ^a   Delafoy Plasse, Laure ^a   Delion, Véronique ^a   Lechevalier, Patricia ^a   Le Bail, Jean Christophe ^a   Guillot, Etienne ^a   Pruniaux, Marie Pierre ^a   Galzin, Anne Marie ^a  

^a SANOFI   (France)

Author keywords

cannabinoid 1 receptor; Glucose tolerance; Insulin secretion; Islet morphology; Rimonabant; Zucker Fatty rat; cell function

Indexed keywords

GLUCOSE; INSULIN; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RELEASE; LONG TERM CARE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; ZUCKER RAT;

EID: 67651125016     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.021     Document Type: Erratum

References (38)

1. Atkinson L.L., Donald-Dyck C., Benkoczi C., and Finegood D.T. Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. Diabetes Obes. Metab. 10 (2007) 780-790
2. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., and Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63 (2003) 908-914
3. Bergeron R., Yao J., Woods J.W., Zycband E.I., Liu C., Li Z., Adams A., Berger J.P., Zhang B.B., Moller D.E., and Doebber T.W. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: a comparison with PPAR gamma agonism. Endocrinology 147 (2006) 4252-4262
4. Bermudez-Silva F.J., Suarez J., Baixeras E., Cobo N., Bautista D., Cuesta-Munoz A.L., Fuentes E., Juan-Pico P., Castro M.J., Milman G., Mechoulam R., Nadal A., and Rodriguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51 (2008) 476-487
5. Buckingham R.E., Al-Barazanji K.A., Toseland C.D., Slaughter M., Connor S.C., West A., Bond B., Turner N.C., and Clapham J.C. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47 (1998) 1326-1334
6. Cavuoto P., McAinch A.J., Hatzinikolas G., Cameron-Smith D., and Wittert G.A. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol. Cell. Endocrinol. 267 (2007) 63-69
7. Cote M., Matias I., Lemieux I., Petrosino S., Almeras N., Despres J.P., and Di Marzo V. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. 31 (2007) 692-699
8. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
9. De Vry J., Schreiber R., Eckel G., and Jentzsch K.R. Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur. J. Pharmacol. 483 (2004) 55-63
10. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8 (2005) 585-589
11. Doyon C., Denis R.G., Baraboi E.D., Samson P., Lalonde J., Deshaies Y., and Richard D. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55 (2006) 3403-3410
12. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., and Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
13. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., Parkes D.G., and Young A.A. Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146 (2005) 2069-2076
14. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
15. Janiak P., Poirier B., Bidouard J.P., Cadrouvele C., Pierre F., Gouraud L., Barbosa I., Dedio J., Maffrand J.P., Le Fur G., O'Connor S., and Herbert J.M. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 72 (2007) 1345-1357
16. Juan-Pico P., Fuentes E., Bermudez-Silva F.J., Diaz-Molina J.F., Ripoll C., Rodriguez de Fonseca F., and Nadal A. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39 (2006) 155-162
17. Kelpe C.L., Johnson L.M., and Poitout V. Increasing triglyceride synthesis inhibits glucose-induced insulin secretion in isolated rat islets of Langerhans: a study using adenoviral expression of diacylglycerol acyltransferase. Endocrinology 143 (2002) 3326-3332
18. Koyama K., Chen G., Lee Y., and Unger R.H. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am. J. Physiol. 273 (1997) E708-E713
19. Larsson L.I., Boder G.B., and Shaw W.N. Changes in the islets of Langerhans in the obese Zucker rat. Lab. Invest. 36 (1977) 593-598
20. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. Relat. Metab. Disord. 29 (2005) 183-187
21. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. (2005) 299-325
22. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocelli L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., and Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91 (2006) 3171-3180
23. Migrenne S., Lacombe A., Lefèvre A.-L., Pruniaux M.-P., Guillot E., Galzin A.-M., and Magnan C. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am. J. Physiol. 296 (2009) R929-R935
24. Milburn J.L., Hirose H., Lee Y.H., Nagasawa Y., Ogawa A., Ohneda M., BeltrandelRio H., Newgard C.B., Johnson J.H., and Unger R.H. Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J. Biol. Chem. 270 (1995) 1295-1299
25. Nakata M., and Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul. Pept. 145 (2008) 49-53
26. Nolan C.J., Leahy J.L., Ghingaro-Augusto V., Moibi J., Soni K., Peyot M.L., Fortier M., Guay C., Lamontagne J., Barbeau A., Przybytkowski E., Joly E., Masiello P., Wang S., Mitchell G.A., and Prentki M. Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia 49 (2006) 2120-2130
27. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., Myers L., Mora Z., Tagliaferro P., Gardner E., Brusco A., Akinshola B.E., Liu Q.R., Hope B., Iwasaki S., Arinami T., Teasenfitz L., and Uhl G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N.Y. Acad. Sci. 1074 (2006) 514-536
28. Osei-Hyiaman D., De Petrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., and Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115 (2005) 1298-1305
29. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
30. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O'Connor S.E., Janiak P., and Herbert J.M. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 7 (2005) 65-72
31. Ravinet-Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., and Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol., Regul. Integr. Comp. Physiol. 284 (2003) R345-R353
32. Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
33. Simiand J., Keane M., Keane P.E., and Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. 9 (1998) 179-181
34. Tharp W.G., Lee Y.H., Maple R.L., and Pratley R.E. The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochem. Biophys. Res. Commun. 372 (2008) 595-600
35. Topp B.G., Atkinson L.L., and Finegood D.T. Dynamics of insulin sensitivity, (-cell function, and -cell mass during the development of diabetes in fa/fa rats. Am. J. Physiol., Endocrinol Metabol. 293 (2007) E1730-E1735
36. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
37. Vickers S.P., Webster L.J., Wyatt A., Dourish C.T., and Kennett G.A. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167 (2003) 103-111
38. Watanabe T., Kubota N., Ohsugi M., Kubota T., Takamoto I., Iwabu M., Awazawa M., Katsuyama H., Hasegawa C., Tokuyama K., Moroi M., Sugi K., Yamauchi T., Noda T., Nagai R., Terauchi Y., Tobe K., Ueki K., and Kadowaki T. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J. Biol. Chem. 284 (2009) 1803-1812